Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIF-1alpha shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intraperitoneal, Inhalation, Intramuscular, Parenteral
01
Overview
HIF-1alpha shRNA (short hairpin RNA targeting hypoxia-inducible factor 1-alpha) is a gene-silencing therapeutic platform designed to downregulate the expression of HIF-1α. HIF-1α is a key transcription factor that mediates cellular responses to hypoxia and is frequently overexpressed in various cancers, promoting angiogenesis, metabolic reprogramming (such as altered choline phospholipid metabolism), and tumor cell survival. By delivering sequence-specific shRNA via viral vectors (such as lentiviruses) or non-viral nanocarriers (such as lipid nanoparticles or polymer complexes), this platform aims to suppress tumor growth, reverse aggressive metabolic phenotypes, and enhance sensitivity to other therapies. It is widely utilized in preclinical oncology research and is being explored for therapeutic translation.
- Other names
- HIF-1 alpha shRNAHIF1 alpha shRNAHIF 1 alpha shRNAHIF-1α shRNAshHIF-1αshHif1ashHif-1ashHif 1ashort hairpin RNA targeting HIF-1alpha
02
Targets
CHKA (Choline kinase)HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on HIF-1alpha shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIF-1alpha shRNA.